EUVIMEDEUVIMED entdecken
EditorialOpen Access

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial

Daniel K Reef iD, Natalie Grover iD

AME Clinical Trials Review · 2026-04 · 4 · 15-15

DOI: 10.21037/actr-25-72 ↗

Kurz gefasst

Editorial in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Daniel K Reef und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Mantle cell lymphoma (MCL)SYMPATICOibrutinibvenetoclax

Autor:innen und Institutionen

  • Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

ORCID-Profile: Daniel K Reef, Natalie Grover

Förderung

  • NCI NIH HHS

Zitieren

APA

Reef, D. K., & Grover, N. (2026). Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review, 4, 15-15. https://doi.org/10.21037/actr-25-72

Vancouver

Reef DK, Grover N. Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review. 2026;4:15-15. doi:10.21037/actr-25-72

BibTeX
@article{Reef2026,
  author = {Reef, Daniel K and Grover, Natalie},
  title = {Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {15--15},
  doi = {10.21037/actr-25-72}
}
Kostenlos starten →